Primary endobronchial melanoma: a case report and clinical management indications.

"Declarations Ethics approval and consent to participateNot applicable: Ethical approval for this case report was not requested. The presented case involves a retrospective analysis of clinical data and medical interventions performed as part of routine patient care. No experimental interventions or additional procedures beyond standard medical practice were conducted. The patient’s privacy and confidentiality have been strictly maintained in accordance with ethical guidelines. As such, formal ethical approval was deemed unnecessary for this retrospective case report. We are committed to adhering to ethical standards in medical research and patient care. Consent for publicationWritten informed consent were obtained from the patient for publication of this case report. Competing interestsETT reported Honoraria for Bristol Myers Squibb; MSD; Pierre Fabre. FS reported Payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events: Novartis, MSD, BMS, Pierre Fabre, Merck, Sanofi, Sun Pharma, IGEA, Philogen. Consulting fees: Novartis, MSD, Sun Pharma, Pierre Fabre, Philogen. All the other authors declare that they have no competing interests. CG reported Honoraria for speaker activity or advisory boards from Astra Zeneca, Bristol-Myers-Squibb, Eli Lilly, Merck-Sharp-Dohme, Novartis, Roche, Sanofi, Takeda. Competing interests ETT reported Honoraria for Bristol Myers Squibb; MSD; Pierre Fabre. FS reported Payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events: Novartis, MSD, BMS, Pierre Fabre, Merck, Sanofi, Sun Pharma, IGEA, Philogen. Consulting fees: Novartis, MSD, Sun Pharma, Pierre Fabre, Philogen. All the other authors declare that they have no competing interests. CG reported Honoraria for speaker activity or advisory boards from Astra Zeneca, Bristol-Myers-Squibb, Eli Lilly, Merck-Sharp-Dohme, Novartis, Roche, Sanofi, Takeda. Competing interests"

"Funding No funding."